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Cell therapy is as old as modern medicine. From blood 
transfusion to allogeneic hematopoietic stem cell trans-
plant, cell therapy in the right settings has been proven to 
save lives. According to the American Red Cross, a total 
of 21 million blood components are transfused each year 
in the United States. The Center for International Blood 
and Marrow Transplant Research reports more than 
50,000 patients worldwide were treated with hematopoi-
etic stem cell transplantation annually.
Unfortunately, cell therapy is also a field that has a 
checkered history, which was plagued at one time or 
another by superstition, blatant medical malpractice, 
and lack of efficacies [1]. At one time blood transfusion 
from animals to humans was used as a punishment for 
human beings who were deemed evil and cadaver blood 
was once thought to be a lucrative commodity. Sadly, 
the discovery of blood types and the coagulation system 
was also associated with heavy tolls as countless lives 
were lost because patients received the “wrong” type or 
preparation of blood products. In the midst of these hor-
rors and the devastating impact on human health, blood 
medicine pioneers learned the hard lesson that blood 
transfusion was vital but was not meant to be done by 
amateurs. As we improved our techniques in dealing with 
blood products, we were humbly reminded of how little 
we actually did understand about the natural law of life as 
transfusions of blood products could occasionally serve 
as a vehicle to transmit once considered fatal diseases 
such as HIV-1 infection and viral hepatitis.
Transfusion medicine has come a long way. It is now a 
vital medical specialty with its own well-established prac-
tices, principles and guidelines [2, 3]. It has cemented 
its place in the foundation of the modern medicine and 
blood therapy is now an undeniably effective and often 
the only treatment modality for a variety of conditions.
There are two fundamental roots to cancer: the cancer-
intrinsic genetic or epigenetic dysregulation of the basic 
biology of the cell, and the failure of the cancer-extrinsic 
host immune defense mechanism known as immune sur-
veillance to eliminate transformed cells [4]. Immunother-
apy is particularly attractive because of its high specificity 
and the ability of the immune system to remember can-
cer cells and mounts a far more efficient immunological 
attack later when cancers recur. Not surprisingly, rejuve-
nating the host immune system for the treatment of can-
cer has been a dream pursued by generations of scientists. 
Presently, with technological advancements and a better 
understanding of the immune system, we are finally able 
to generate billions of T lymphocytes with defined anti-
gen specificity, natural killer cells, as well as professional 
antigen-presenting cells such as dendritic cells [5]. Syn-
thetic immunologists are especially proud of re-directing 
T cell antigen-specificity via enforcing the expression of 
chimeric antigen receptors and deleting the endogenous 
T cell receptor or other regulatory molecules such as pro-
gram death 1 molecule (PD-1) via gene editing [6]. This 
has sparked a tremendous level of interests from the pub-
lic for the miracle cures that immunotherapy might be 
able to deliver. Such a high level of enthusiasm was often 
further fueled by press releases and anecdotal reports of 
the wonder of killer cells in one form or another in ani-
mal studies or in early-phase clinical trials. Unfortunately, 
cell therapy for cancer is still at its experimental stage. The 
only US Food and Drug Administration (FDA)-approved 
cell therapy for cancer (excluding hematopoietic stem 
cell transplant), is sipuleucel-T which is indicated for the 
treatment of asymptomatic or minimally symptomatic 
metastatic castration-resistant (hormone refractory) pros-
tate cancer [7]. Alarmingly, despite warnings from scien-
tists, there is a widespread commercial use of cell therapy 
of unclear and unproven efficacy in cancer patients. This 
is particularly worrisome in countries where there is no 
clear-cut regulatory mechanism governing the practice of 
cell-based therapy for desperate cancer patients.
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The exact number of patients who were given unproven 
cell therapy was unclear and might never be known, as 
the experience of these patients was rarely published 
in peer-reviewed international journals. It is less clear 
whether or not any of these patients had any meaningful 
clinical benefits and worse yet if more harms were done, 
medically or economically, to them. In examining some 
of the published work, it was often unclear if clinical 
studies were conducted under proper supervision by reg-
ulatory agencies and local institutional review boards. It 
was uncertain if these cellular products such as dendritic 
cells, or “cytokine-activated killer cells” that were admin-
istered to patients were manufactured under the princi-
ples of good manufacturing practice (GMP) with proper 
quality controls.
We believe that the application of cell therapy in 
human subjects under no clear scientific, ethical and 
regulatory monitoring by the pertinent agencies and 
policy makers is no better than an act of witchcraft. This 
practice is tainting the name of science, scientists or 
physicians alike. Worse yet, it puts the vulnerable public 
(i.e., the consumers or the patients) in a harm’s way. Lack 
of safeguard measures and quality controls to prevent 
adverse effects is unfortunately not uncommon. Since 
the outcome of the treatment is often not documented 
well and communicated to the scientific and medical 
community, the public is left without any analyzable sci-
entific data to gain important knowledge to advance the 
medicine.
Encouragingly, the medical and research commu-
nity is acutely aware of the lack of global standards in 
the practice of cell therapy and has been calling for 
actions. The US FDA continues to release guidance 
documents, describing the FDA’s current thinking on 
this topic (http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guid-
ances/CellularandGeneTherapy/). There is an ongoing 
debate elsewhere on whether cell-based therapy for can-
cer should be regulated as a medicine or can be merely 
regarded as a technology, which of course is under dif-
ferent jurisdictions. However, there is a high hope that 
the sweeping scientifically sound and responsible regu-
latory policy will be put in place in guiding cell therapy 
for cancer in both developed and developing countries. 
At the same time, unfortunately,  many more patients 
continue to be treated by the experimental cell therapy 
without approval by the proper regulatory authorities; 
this include wide spread use of stem cells in non-cancer 
conditions [8–10]. For the sake of protecting patients, 
it is time now to halt such a practice until the appropri-
ate regulatory policy is put in place. We believe in the 
power of science and by no means are calling for stop-
ping proper clinical trials that unleash the wonder of 
immunology or stem cells. We are firmly convinced that 
meaningful conclusion cannot be drawn if clinical stud-
ies are not conducted correctly and ethically. In the case 
of unproven and unregulated commercial practice of cell 
therapy for cancer, it runs the risk of causing more harm 
than good to our patients, which we collectively have a 
moral and professional obligation to oppose.
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